Variables* | AS, n = 639 | nr-axSpA, n = 73 | p |
---|---|---|---|
Male % | 76.2 | 47.9 | < 0.0001† |
HLA-B27 positive, % | 78.9 | 72.5 | 0.21 |
Age at last visit, yrs | 41.4 (13.6) | 37.7 (12.7) | 0.05 |
Age at time of diagnosis, yrs | 30.5 (11.7) | 32.2 (12.0) | 0.11 |
Age at symptom onset, yrs | 23.9 (9.8) | 26.4 (10.6) | 0.03 |
Time from symptom onset to diagnosis, yrs | 6.7 (7.9) | 5.5 (6.3) | 0.28 |
Disease duration at last clinic visit, yrs | 17.7 (12.3) | 12.1 (8.5) | 0.0002† |
Currently unemployed due to disability from AS, % | 15.6 | 6.9 | 0.05 |
Current NSAID use, % | 68.8 | 72.2 | 0.59 |
Current DMARD use, % | 18.4 | 18.8 | 1.00 |
Current glucocorticoid use, % | 5.6 | 4.1 | 0.79 |
Ever biologic use, % | 44.4 | 42.5 | 0.80 |
Current biologic use, % | 43.6 | 34.3 | 0.16 |
CRP, mg/l | 11.4 (14.9) | 5.2 (5.3) | < 0.0001† |
ESR, mm/h | 13.7 (14.2) | 9.9 (11.9) | 0.02† |
Total back pain, VAS, 0–10 | 4.4 (2.5) | 4.7 (2.8) | 0.46 |
BASDAI | 4.4 (2.3) | 4.7 (2.2) | 0.35 |
BASMI | 2.8 (2.5) | 1.4 (1.2) | < 0.0001† |
BASFI | 3.6 (2.6) | 3.0 (2.4) | 0.05 |
BAS-G | 4.8 (2.4) | 5.2 (2.5) | 0.29 |
HAQ-DI | 0.65 (0.58) | 0.57 (0.48) | 0.27 |
SF-36 mental component | 46.4 (10.7) | 45.7 (10.7) | 0.63 |
SF-36 physical component | 38.2 (10.2) | 37.9 (10.8) | 0.80 |
Fatigue severity scale | 5.1 (2.6) | 5.2 (2.6) | 0.68 |
ASQoL | 7.4 (5.5) | 7.1 (5.2) | 0.60 |
EQ-5D | 0.70 (0.21) | 0.67 (0.19) | 0.41 |
History of fibromyalgia, % | 6.1 | 13.7 | 0.02† |
History of uveitis, % | 29.2 | 27.4 | 0.79 |
History of psoriasis, % | 9.4 | 9.6 | 0.98 |
History of IBD, % | 12.5 | 11.0 | 0.85 |
Ever smoker, % | 43.0 | 41.1 | 0.81 |
Current smoker, % | 23.2 | 18.3 | 0.37 |
↵* Values are mean (SD) unless stated otherwise.
↵† Statistically significant. NSAID: nonsteroidal antiinflammatory drug; DMARD: disease-modifying antirheumatic drug; VAS: visual analog scale; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASMI: Bath Ankylosing Spondylitis Metrology Index; BASFI: Bath Ankylosing Spondylitis Functional Index; BAS-G: Bath Ankylosing Spondylitis patient Global score; ASQoL: Ankylosing Spondylitis Quality of Life score; EQ-5D: European Quality of Life 5 Dimensions questionnaire; CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire–Disability Index; SF-36: Medical Outcomes Study Short Form-36 questionnaire; IBD: inflammatory bowel disease.